CSL Behring gets positive IQWiG assessment for garadacimab

26 June 2025

Australian biotech CSL Limited (ASX: CSL) Europe-based subsidiary CSL Behring announced a milestone in the early benefit assessment of garadacimab by Germany’s Institute for Quality and Efficiency in Health Care (IQWiG).

Garadacimab is a unique once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.

The IQWiG has acknowledged that, for the first time, suitable data are available in the indication of hereditary angioedema for a comparison with the appropriate comparative therapy. According to the official IQWiG summary, the benefit assessment was based on a methodologically sound indirect comparison using placebo as a common comparator.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK